Population pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated malaria

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 4, 2012, Pages 1997-2007

  Tarning, Joel ^a,b   Rijken, Marcus J ^c   McGready, Rose ^a,b,c   Phyo, Aung Pyae ^c   Hanpithakpong, Warunee ^a   Day, Nicholas P J ^a,b   White, Nicholas J ^a,b   Nosten, François ^a,b,c   Lindegardh, Niklas ^a,b  

^a MAHIDOL UNIVERSITY   (Thailand)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c SHOKLO MALARIA RESEARCH UNIT   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROARTEMISININ; PIPERAQUINE;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HUMAN; HUMAN TISSUE; MALARIA FALCIPARUM; MYANMAR; PARASITE CLEARANCE; PLASMODIUM VIVAX MALARIA; POPULATION RESEARCH; PREGNANCY; PREGNANT WOMAN; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PROPHYLAXIS; THAILAND; THIRD TRIMESTER PREGNANCY; TREATMENT DURATION; VENOUS BLOOD;

ADOLESCENT; ADULT; ANTIMALARIALS; AREA UNDER CURVE; ARTEMISININS; BODY WEIGHT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HALF-LIFE; HUMANS; MALARIA; MIDDLE AGED; MYANMAR; NONLINEAR DYNAMICS; POPULATION; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY COMPLICATIONS, PARASITIC; QUINOLINES; SOFTWARE; TANDEM MASS SPECTROMETRY; THAILAND; YOUNG ADULT;

EID: 84858669751     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05756-11     Document Type: Article

References (62)

1. Ahn JE, Karlsson MO, Dunne A, Ludden TM. 2008. Likelihood based approaches to handling data below the quantification limit using NONMEM VI. J. Pharmacokinet. Pharmacodyn. 35:401-421.
2. Anderson GD. 2005. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clin. Pharmacokinet. 44:989-1008. (Pubitemid 41356388)
3. Annerberg A, et al. 2011. A small amount of fat does not affect piperaquine exposure in patients with malaria. Antimicrob. Agents Chemother. 55:3971-3976.
4. Beal SL. 2001. Ways to fit a PK model with some data below the quantification limit. J. Pharmacokinet. Pharmacodyn. 28:481-504. (Pubitemid 33151426)
5. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. 2011. Predictioncorrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 13:143-151.
6. Bergstrand M, Karlsson MO. 2009. Handling data below the limit of quantification in mixed effect models. AAPS J. 11:371-380.
7. Binh TQ, et al. 2001. Oral bioavailability of dihydroartemisinin in Vietnamese volunteers and in patients with falciparum malaria. Br. J. Clin. Pharmacol. 51:541-546. (Pubitemid 32862743)
8. Brabin BJ, Agbaje SO, Ahmed Y, Briggs ND. 1999. A birthweight nomogram for Africa, as a malaria-control indicator. Ann. Trop. Med. Parasitol. 93(Suppl. 1):S43-S57. (Pubitemid 30062188)
9. Brabin BJ, et al. 2004. The sick placenta - the role of malaria. Placenta 25:359-378. (Pubitemid 38519110)
10. Brockman A, et al. 1999. Application of genetic markers to the identification of recrudescent Plasmodium falciparum infections on the northwestern border of Thailand. Am. J. Trop. Med. Hyg. 60:14-21. (Pubitemid 29065997)
11. Chinh NT, et al. 2009. Pharmacokinetics and bioequivalence evaluation of two fixed-dose tablet formulations of dihydroartemisinin and piperaquine in Vietnamese subjects. Antimicrob. Agents Chemother. 53:828-831.
12. Dawes M, Chowienczyk PJ. 2001. Drugs in pregnancy. Pharmacokinetics in pregnancy. Best Pract. Res. Clin. Obstet. Gynaecol. 15:819-826.
13. Dellicour S, Tatem AJ, Guerra CA, Snow RW, ter Kuile FO. 2010. Quantifying the number of pregnancies at risk of malaria in 2007: a demographic study. PLoS Med. 7:e1000221.
14. Dondorp AM, et al. 2009. Artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med. 361:455-467.
15. Green MD, et al. 2007. Pharmacokinetics of sulfadoxine-pyrimethamine in HIV-infected and uninfected pregnant women in western Kenya. J. Infect. Dis. 196:1403-1408. (Pubitemid 351412014)
16. Hai TN, Hietala SF, Van Huong N, Ashton M. 2008. The influence of food on the pharmacokinetics of piperaquine in healthy Vietnamese volunteers. Acta Trop. 107:145-149.
17. Hanpithakpong W, et al. 2008. A liquid chromatographic-tandem mass spectrometric method for determination of artesunate and its metabolite dihydroartemisinin in human plasma. J. Chromatogr. 876:61-68.
18. Haynes RK, et al. 2007. Artesunate and dihydroartemisinin (DHA): unusual decomposition products formed under mild conditions and comments on the fitness of DHA as an antimalarial drug. ChemMedChem 2:1448-1463.
19. Hong X, et al. 2008. Pharmacokinetics of dihydroartemisinin in Artekin tablets for single and repeated dosing in Chinese healthy volunteers. Biopharm. Drug Dispos. 29:237-244. (Pubitemid 351802846)
20. Hooker AC, Staatz CE, Karlsson MO. 2007. Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method. Pharm. Res. 24:2187-2197. (Pubitemid 350060706)
21. Hung TY, et al. 2004. Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria. Br. J. Clin. Pharmacol. 57:253-262.
22. Ilett KF, et al. 2002. Glucuronidation of dihydroartemisinin in vivo and by humanliver microsomes and expressed UDP-glucuronosyltransferases.Drug Metab. Dispos. 30:1005-1012.
23. Jonsson EN, Karlsson MO. 1999. Xpose - an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput. Methods Programs Biomed. 58:51-64. (Pubitemid 29049052)
24. Karunajeewa HA, et al. 2008. Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria. Antimicrob. Agents Chemother. 52:237-243.
25. Karunajeewa HA, et al. 2009. Pharmacokinetic properties of sulfadoxinepyrimethamine in pregnant women. Antimicrob. Agents Chemother. 53: 4368-4376.
26. Le NH, Na-Bangchang K, Le TD, Thrinh KA, Karbwang J. 1999. Phamacokinetics of a single oral dose of dihydroartemisinin in Vietnamese healthy volunteers. Southeast Asian J. Trop. Med. Public Health 30: 11-16.
27. Le Thi DT, Le NH, Nguyen CH, Phan Thi D, Na-Bangchang K. 2008. Pharmacokinetics of a five-day oral dihydroartemisinin monotherapy regimen in patients with uncomplicated falciparum malaria. Drug Metab. Pharmacokinet. 23:158-164.
28. Lindbom L, Pihlgren P, Jonsson EN. 2005. PsN-toolkit - a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput. Methods Programs Biomed. 79:241-257. (Pubitemid 41196689)
29. Lindbom L, Ribbing J, Jonsson EN. 2004. Perl-speaks-NONMEM (PsN) - a Perl module for NONMEM related programming. Comput. Methods Programs Biomed. 75:85-94. (Pubitemid 38798039)
30. Lindegardh N, White NJ, Day NP. 2005. High throughput assay for the determination of piperaquine in plasma. J. Pharm. Biomed. Anal. 39:601-605. (Pubitemid 41196069)
31. Little BB. 1999. Pharmacokinetics during pregnancy: evidence-based maternal dose formulation. Obstet. Gynecol. 93:858-868. (Pubitemid 29197933)
32. McGready R, et al. 28 September 2011. Artesunate/dihydroartemisinin pharmacokinetics in acute falciparum malaria in pregnancy: absorption, bioavailability, disposition and disease effects. Br. J. Clin. Pharmacol. [Epub ahead of print.] doi:10.1111/j.1365-2125.2011.04103.x.
33. McGready R, et al. 2003. The pharmacokinetics of atovaquone and proguanil in pregnant women with acute falciparum malaria. Eur. J. Clin. Pharmacol. 59:545-552. (Pubitemid 37368905)
34. McGready R, et al. 2006. The pharmacokinetics of artemether and lumefantrine in pregnant women with uncomplicated falciparum malaria. Eur. J. Clin. Pharmacol. 62:1021-1031. (Pubitemid 44786494)
35. McGready R, et al. 2003. Pregnancy and use of oral contraceptives reduces the biotransformation of proguanil to cycloguanil. Eur. J. Clin. Pharmacol. 59:553-557. (Pubitemid 37363567)
36. McGready R, et al. 2006. Pharmacokinetics of dihydroartemisinin following oral artesunate treatment of pregnant women with acute uncomplicated falciparum malaria. Eur. J. Clin. Pharmacol. 62:367-371.
37. Na-Bangchang K, Thanavibul A, Tippawangkosol P, Karbwang J. 2005. Pharmacokinetics of the four combination regimens of dihydroartemisinin/ mefloquine in acute uncomplicated falciparum malaria. Southeast Asian J. Trop. Med. Public Health 36:23-33. (Pubitemid 40576990)
38. Na-Bangchang K, Tippawangkosol P, Thanavibul A, Ubalee R, Karbwang J. 1999. Pharmacokinetic and pharmacodynamic interactions of mefloquine and dihydroartemisinin. Int. J. Clin. Pharmacol. Res. 19:9-17. (Pubitemid 29363951)
39. Newton PN, et al. 2002. Comparison of oral artesunate and dihydroartemisinin antimalarial bioavailabilities in acute falciparum malaria. Antimicrob. Agents Chemother. 46:1125-1127. (Pubitemid 34260366)
40. Nguyen DV, et al. 2009. Pharmacokinetics and ex vivo pharmacodynamic antimalarial activity of dihydroartemisinin-piperaquine in patients with uncomplicated falciparum malaria in Vietnam. Antimicrob. Agents Chemother. 53:3534-3537.
41. Nguyen TC, et al. 2008. Pharmacokinetics of the antimalarial drug piperaquine in healthy Vietnamese subjects. Am. J. Trop. Med. Hyg. 79:620-623.
42. Nosten F, et al. 1999. Effects of Plasmodium vivax malaria in pregnancy. Lancet 354:546-549. (Pubitemid 29381368)
43. Nosten F, ter Kuile F, Maelankirri L, Decludt B, White NJ. 1991. Malaria during pregnancy in an area of unstable endemicity. Trans. R. Soc. Trop. Med. Hyg. 85:424-429.
44. Nyunt MM, et al. 2010. Pharmacokinetics of sulfadoxine and pyrimethamine in intermittent preventive treatment of malaria in pregnancy. Clin. Pharmacol. Ther. 87:226-234.
45. Rijken MJ, et al. 2008. Dihydroartemisinin-piperaquine rescue treatment of multidrug-resistant Plasmodium falciparum malaria in pregnancy: a preliminary report. Am. J. Trop. Med. Hyg. 78:543-545. (Pubitemid 351845153)
46. Rijken MJ, et al. 2011. Pharmacokinetics of amodiaquine and desethylamodiaquine in pregnant and postpartum women with Plasmodium vivax malaria. Antimicrob. Agents Chemother. 55:4338-4342.
47. Rijken MJ, et al. 2011. The pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated falciparum malaria. Antimicrob. Agents Chemother. 55:5500-5506.
48. Rogerson SJ, Hviid L, Duffy PE, Leke RF, Taylor DW. 2007. Malaria in pregnancy: pathogenesis and immunity. Lancet Infect. Dis. 7:105-117. (Pubitemid 46123133)
49. Roshammar D, Hai TN, Friberg Hietala S, Van Huong N, Ashton M. 2006. Pharmacokinetics of piperaquine after repeated oral administration of the antimalarial combination CV8 in 12 healthy male subjects. Eur. J. Clin. Pharmacol. 62:335-341.
50. Rousseau A, et al. 2004. Population pharmacokinetic modeling of oral cyclosporin using NONMEM: comparison of absorption pharmacokinetic models and design of a Bayesian estimator. Ther. Drug Monit. 26: 23-30. (Pubitemid 38140906)
51. Savic RM, Jonker DM, Kerbusch T, Karlsson MO. 2007. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J. Pharmacokinet. Pharmacodyn. 34:711-726. (Pubitemid 47477040)
52. Savic RM, Karlsson MO. 2009. Importance of shrinkage in empirical Bayes estimates for diagnostics: problems and solutions. AAPS J. 11:558-569.
53. Sim IK, Davis TM, Ilett KF. 2005. Effects of a high-fat meal on the relative oral bioavailability of piperaquine. Antimicrob. Agents Chemother. 49: 2407-2411. (Pubitemid 40734473)
54. Srinivas NR. 2009. Dihydroartemisinin pharmacokinetics in patients with malaria after multiple doses - assembling clues and perspectives. Drug Metab. Pharmacokinet. 24:282-284.
55. Tarning J, et al. 2008. Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand. Antimicrob. Agents Chemother. 52:1052-1061. (Pubitemid 351358388)
56. Tarning J, et al. 2005. Pitfalls in estimating piperaquine elimination. Antimicrob. Agents Chemother. 49:5127-5128. (Pubitemid 41778931)
57. Tarning J, et al. 2008. Pharmacokinetics and metabolism of the antimalarial piperaquine after intravenous and oral single doses to the rat. J. Pharm. Sci. 97:3400-3410.
58. Tarning J, et al. 2009. Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria. Antimicrob. Agents Chemother. 53:3837-3846.
59. White NJ. 2005. Intermittent presumptive treatment for malaria. PLoS Med. 2:e3.
60. WHO. 2010. World Health Organization guidelines for the treatment of malaria. WHO, Geneva, Switzerland.
61. Wilkins JJ. 2005. NONMEMory: a run management tool for NONMEM. Comput. Methods Programs Biomed. 78:259-267. (Pubitemid 40719673)
62. Zwang J, et al. 2009. Safety and efficacy of dihydroartemisininpiperaquine in falciparum malaria: a prospective multi-centre individual patient data analysis. PLoS One 4:e6358.